Week In Review: OrbiMed Raises $800 Million For Its Fourth Asia Fund

OrbiMed Advisors announced it has secured $3.5 billion in commitments for its latest capital raise, including $800 million for OrbiMed Asia Partners IV. Connect Biopharma of Taicang has filed for a NASDAQ IPO that could raise $100 million.